Celularity (CELU)
NASDAQ:CELU
Want to see CELU full AI Analyst Report?
CELU Stock Chart & Stats
$1.25
-$0.06(-2.69%)
At close: 4:00 PM EST
$1.25
-$0.06(-2.69%)
Day’s Range― - ―
52-Week Range$0.67 - $4.35
Previous Close$2.13
Volume115.00K
Average Volume (3M)206.82K
Market Cap
$21.78M
Enterprise Value$53.88M
Total Cash (Recent Filing)$6.17M
Total Debt (Recent Filing)$40.90M
Price to Earnings (P/E)―
Beta3.04
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.69
Shares Outstanding28,945,961
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.75
Price to Sales (P/S)1.07
P/FCF Ratio-2.14
Enterprise Value/Market Cap2.47
Enterprise Value/Revenue2.03
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-0.69
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Bulls Say, Bears Say
Bulls Say
Allogeneic Cell Therapy PlatformCelularity’s proprietary placental and umbilical-tissue platform underpins off-the-shelf allogeneic therapies and multiple programs (NK cells, stromal cells). This asset base supports scalable manufacturing, repeatable product cycles and potential broad clinical applicability, a durable competitive foundation for commercialization.
Improving Cash Generation TrajectoryReduced cash burn and materially narrower free cash flow losses over 2024–2025 extend runway and lower near-term financing pressure. A sustained improvement in cash outflows increases the company’s ability to execute clinical and commercial milestones without immediate, large dilutive financings.
Asset Monetization And Debt ReductionThe NexGel sale generated cash, a convertible note and removed ~ $13M of debt while preserving milestone/royalty upside. This strategic divestiture refocuses resources on core cell-therapy programs and meaningfully improves balance-sheet flexibility over the medium term.
Bears Say
Negative Equity And Elevated LeverageNegative shareholders’ equity and elevated leverage materially constrain financial flexibility and raise refinancing and dilution risk. Persistently weak equity limits borrowing capacity, increases lender covenants/terms, and can impair the company’s ability to fund clinical development or commercial scale-up without dilutive capital.
Revenue Contraction And Sustained LossesA sharp revenue decline and ongoing negative EBIT show the business has not achieved scalable commercial traction. Structural revenue weakness reduces internal funding for R&D and manufacturing, prolongs dependence on external capital, and challenges long-term margin sustainability.
Nasdaq Listing Compliance RiskA formal Nasdaq compliance notice introduces a multi-month regulatory overhang that can force dilutive actions or limit strategic options if market value is not restored. Delisting risk materially affects access to public capital markets and can damage supplier, partner and investor confidence over the medium term.
Celularity News
CELU FAQ
What was Celularity’s price range in the past 12 months?
Celularity lowest stock price was $0.67 and its highest was $4.35 in the past 12 months.
What is Celularity’s market cap?
Celularity’s market cap is $21.78M.
When is Celularity’s upcoming earnings report date?
Celularity’s upcoming earnings report date is Apr 01, 2027 which is in 285 days.
How were Celularity’s earnings last quarter?
Currently, no data Available
Is Celularity overvalued?
According to Wall Street analysts Celularity’s price is currently Overvalued.
Does Celularity pay dividends?
Celularity does not currently pay dividends.
What is Celularity’s EPS estimate?
Celularity’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Celularity have?
Celularity has 28,945,961 shares outstanding.
What happened to Celularity’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Celularity?
Currently, no hedge funds are holding shares in CELU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Celularity
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
Technical Analysis
Ownership Overview
36.47% Insiders
2.63% Mutual Funds
3.16% Other Institutional Investors
55.42% Public Companies and
Individual Investors